Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27143076 | 0.88 | FABP5 (0.52) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL14590853 | 0.82 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL44676 | 0.81 | KMT2A (0.58) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL14099780 | 0.81 | CYP1A2 (0.47) | FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL9647974 | 0.80 | KMT2A (0.43) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL9355666 | 0.80 | KMT2A (0.43) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL15058849 | 0.78 | KMT2A (0.55) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL9225108 | 0.78 | GAA (0.49) | FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL9225114 | 0.77 | FABP5 (0.44) | FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL29996541 | 0.75 | KMT2A (0.47) | FABP5FABP7KMT2AEPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076294-B2 | Collagen-related peptides and uses thereof | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090299034-A1 | Collagen-related peptides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-12-03 | — | — | US | disclosed |
| US-20090068246-A1 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF | ETHICON, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299034-A1 | Collagen-related peptides | COL14A1, COL2A1, COL1A1 | FABP5 450/4885FABP7 906/4885KMT2A 4250/4885 |
| US-20090068246-A1 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF | COL14A1, COL2A1, COL1A1 | FABP5 559/4885FABP7 953/4885KMT2A 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.